## Young Chul Youn

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3708500/publications.pdf

Version: 2024-02-01

257101 2,125 127 24 citations h-index papers

40 g-index 157 157 157 3350 docs citations times ranked citing authors all docs

288905

#	Article	IF	CITATIONS
1	Prevalence, risk factors and consequences of cerebral small vessel diseases: data from three Asian countries. Journal of Neurology, Neurosurgery and Psychiatry, 2017, 88, 669-674.	0.9	151
2	The genetics of Alzheimer's disease. Clinical Interventions in Aging, 2014, 9, 535.	1.3	131
3	Oligomeric forms of amyloid-β protein in plasma as a potential blood-based biomarker for Alzheimer's disease. Alzheimer's Research and Therapy, 2017, 9, 98.	3.0	108
4	Genetic analyses of early-onset Alzheimer's disease using next generation sequencing. Scientific Reports, 2019, 9, 8368.	1.6	91
5	Serum Vitamin D Status as a Predictor of Prognosis in Patients with Acute Ischemic Stroke. Cerebrovascular Diseases, 2015, 40, 73-80.	0.8	75
6	Clinical Characteristics of a Nationwide Hospital-based Registry of Mild-to-Moderate Alzheimer's Disease Patients in Korea: A CREDOS (Clinical Research Center for Dementia of South Korea) Study. Journal of Korean Medical Science, 2011, 26, 1219.	1.1	63
7	Artificial Neural Network: Understanding the Basic Concepts without Mathematics. Dementia and Neurocognitive Disorders, 2018, 17, 83.	0.4	62
8	Dynamic changes of oligomeric amyloid $\hat{l}^2$ levels in plasma induced by spiked synthetic A $\hat{l}^2$ 42. Alzheimer's Research and Therapy, 2017, 9, 86.	3.0	57
9	Characterization of mutations in <em>PRNP</em> (prion) gene and their possible roles in neurodegenerative diseases. Neuropsychiatric Disease and Treatment, 2018, Volume 14, 2067-2085.	1.0	56
10	Deep learning for EEG data analytics: A survey. Concurrency Computation Practice and Experience, 2020, 32, e5199.	1.4	50
11	Impact of White Matter Changes on Activities of Daily Living in Mild to Moderate Dementia. European Neurology, 2011, 65, 223-230.	0.6	45
12	Intracranial Internal Carotid Artery Calcification: A Representative for Cerebral Artery Calcification and Association with White Matter Hyperintensities. Cerebrovascular Diseases, 2010, 30, 65-71.	0.8	42
13	Effect of high-frequency repetitive transcranial magnetic stimulation on major depressive disorder in patients with Parkinson's disease. Journal of Neurology, 2016, 263, 1442-1448.	1.8	41
14	Coping with Dementia in the Middle of the COVID-19 Pandemic. Journal of Korean Medical Science, 2020, 35, e383.	1.1	40
15	APP, PSEN1, and PSEN2 Mutations in Asian Patients with Early-Onset Alzheimer Disease. International Journal of Molecular Sciences, 2019, 20, 4757.	1.8	38
16	Blood amyloid-β oligomerization associated with neurodegeneration of Alzheimer's disease. Alzheimer's Research and Therapy, 2019, 11, 40.	3.0	38
17	Protective effect of boldine on dopamine-induced membrane permeability transition in brain mitochondria and viability loss in PC12 cells. Biochemical Pharmacology, 2002, 63, 495-505.	2.0	37
18	Prediction of cognitive impairment via deep learning trained with multi-center neuropsychological test data. BMC Medical Informatics and Decision Making, 2019, 19, 231.	1.5	37

#	Article	IF	CITATIONS
19	Blood Amyloid-β Oligomerization as a Biomarker of Alzheimer's Disease: A Blinded Validation Study. Journal of Alzheimer's Disease, 2020, 75, 493-499.	1.2	35
20	Etiology of aseptic meningitis and clinical characteristics in immune ompetent adults. Journal of Medical Virology, 2016, 88, 175-179.	2.5	34
21	Effects of Medial Temporal Atrophy and White Matter Hyperintensities on the Cognitive Functions in Patients with Alzheimer's Disease. European Neurology, 2011, 66, 75-82.	0.6	33
22	Depressive Symptoms are Associated with Progression to Dementia in Patients with Amyloid-Positive Mild Cognitive Impairment. Journal of Alzheimer's Disease, 2017, 58, 1255-1264.	1.2	31
23	Evaluation of coexistence of Alzheimer's disease in idiopathic normal pressure hydrocephalus using ELISA analyses for CSF biomarkers. BMC Neurology, 2014, 14, 66.	0.8	30
24	Clinical practice guideline for dementia by Clinical Research Center for Dementia of South Korea. Journal of the Korean Medical Association, 2011, 54, 861.	0.1	26
25	Genetic Factors of Cerebral Small Vessel Disease and Their Potential Clinical Outcome. International Journal of Molecular Sciences, 2019, 20, 4298.	1.8	25
26	Probable novel PSEN2 Val214Leu mutation in Alzheimer's disease supported by structural prediction. BMC Neurology, 2014, 14, 105.	0.8	24
27	Mutations, associated with early-onset Alzheimer's disease, discovered in Asian countries. Clinical Interventions in Aging, 2016, Volume 11, 1467-1488.	1.3	24
28	Selfâ€and informantâ€reported cognitive functioning and awareness in subjective cognitive decline, mild cognitive impairment, and very mild Alzheimer disease. International Journal of Geriatric Psychiatry, 2020, 35, 91-98.	1.3	24
29	Brachial-ankle pulse wave velocity is associated with both acute and chronic cerebral small vessel disease. Atherosclerosis, 2016, 245, 54-59.	0.4	23
30	Use of the Clock Drawing Test and the Rey–Osterrieth Complex Figure Test-copy with convolutional neural networks to predict cognitive impairment. Alzheimer's Research and Therapy, 2021, 13, 85.	3.0	23
31	Voxel-based morphometric study of brain volume changes in patients with Alzheimer's disease assessed according to the Clinical Dementia Rating score. Journal of Clinical Neuroscience, 2011, 18, 916-921.	0.8	22
32	Rivastigmine patch reduces the incidence of postoperative delirium in older patients with cognitive impairment. International Journal of Geriatric Psychiatry, 2017, 32, 1079-1084.	1.3	21
33	Clinical and Neuropsychological Comparisons of Early-Onset Versus Late-Onset Frontotemporal Dementia: A CREDOS-FTD Study. Journal of Alzheimer's Disease, 2015, 45, 599-608.	1.2	19
34	A Comprehensive Visual Rating Scale of Brain Magnetic Resonance Imaging: Application in Elderly Subjects with Alzheimer's Disease, Mild Cognitive Impairment, and Normal Cognition. Journal of Alzheimer's Disease, 2015, 44, 1023-1034.	1.2	19
35	A voxel-based morphometric study of cortical gray matter volume changes in Alzheimer's disease with white matter hyperintensities. Journal of Clinical Neuroscience, 2012, 19, 1506-1510.	0.8	18
36	Detection of cognitive impairment using a machine-learning algorithm. Neuropsychiatric Disease and Treatment, 2018, Volume 14, 2939-2945.	1.0	18

#	Article	IF	CITATIONS
37	Clinical utility of serum hepcidin and iron profile measurements in Alzheimer's disease. Journal of the Neurological Sciences, 2019, 403, 85-91.	0.3	18
38	Effect of White Matter Hyperintensity on Medial Temporal Lobe Atrophy in Alzheimer's Disease. European Neurology, 2013, 69, 229-235.	0.6	17
39	Analysis of Cerebrospinal Fluid and [11C]PIB PET Biomarkers for Alzheimer's Disease with Updated Protocols. Journal of Alzheimer's Disease, 2016, 52, 1403-1413.	1.2	17
40	Glycyrrhizin Prevents 7-Ketocholesterol Toxicity Against Differentiated PC12 Cells by Suppressing Mitochondrial Membrane Permeability Change. Neurochemical Research, 2009, 34, 1433-1442.	1.6	16
41	Novel PSEN1 p.Gly417Ala mutation in a Korean patient with early-onset Alzheimer's disease with parkinsonism. Neurobiology of Aging, 2018, 72, 188.e13-188.e17.	1.5	16
42	A Comparative Evaluation of the KDSQ-C, AD8, and SMCQ as a Cognitive Screening Test to Be Used in National Medical Check-ups in Korea. Journal of Korean Medical Science, 2019, 34, e111.	1.1	16
43	A Consensus in Korea Regarding a Protocol to Reduce Preanalytical Sources of Variability in the Measurement of the Cerebrospinal Fluid Biomarkers of Alzheimer's Disease. Journal of Clinical		

#	Article	IF	CITATIONS
55	Neuropsychological Correlates of the Proportional Impact of White Matter Hyperintensities on Mild to Moderate Dementia: The MRI 300 Study. Dementia and Geriatric Cognitive Disorders, 2011, 31, 397-405.	0.7	11
56	Posterior atrophy predicts time to dementia in patients with amyloid-positive mild cognitive impairment. Alzheimer's Research and Therapy, 2017, 9, 99.	3.0	11
57	Cerebrospinal Fluid Levels of Î <sup>2</sup> -Amyloid 40 and Î <sup>2</sup> -Amyloid 42 are Proportionately Decreased in Amyloid Positron-Emission Tomography Negative Idiopathic Normal-Pressure Hydrocephalus Patients. Journal		

#	Article	IF	Citations
73	Neuroleptic malignant syndrome induced by phenytoin in a patient with drug-induced Parkinsonism. Neurological Sciences, 2014, 35, 1641-1643.	0.9	6
74	Age-Specific Cutoff Scores on a T1-Weighted Axial Medial Temporal-Lobe Atrophy Visual Rating Scale in Alzheimer's Disease Using Clinical Research Center for Dementia of South Korea Data. Journal of		

#	Article	IF	Citations
91	Machineâ€learning based EEG biomarker for early screening of amnestic mild cognitive impairment (aMCI). Alzheimer's and Dementia, 2020, 16, e044381.	0.4	2
92	Dynamic association between AT(N) profile and cognition mediated by cortical thickness in Alzheimer's continuum. NeuroImage: Clinical, 2020, 27, 102282.	1.4	2
93	A Voxel Based Morphometric Analysis of Longitudinal Cortical Gray Matter Changes in Progranulin Mutation Carriers At-Risk for Frontotemporal Dementia: Preliminary Study. Dementia and Neurocognitive Disorders, 2015, 14, 163.	0.4	2
94	Steroid responsive rhombencephalitis and optic neuritis with autoimmune thyroid disease. Neurological Sciences, 2015, 36, 813-815.	0.9	1
95	P2â€092: Novel, PSEN1 T119I Mutation in an Earlyâ€Onset Alzheimer's Disease Patient. Alzheimer's and Dementia, 2016, 12, P645.	0.4	1
96	Depressive Symptoms and Cognitive Improvement in Patients with Dementia with Lewy Bodies. Journal of Alzheimer's Disease, 2019, 71, 899-905.	1.2	1
97	Cerebellar distortion after a cystoperitoneal shunt for arachnoid cyst. Neurology India, 2011, 59, 467.	0.2	1
98	A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase IIb Clinical Study to Evaluate the Safety and Efficacy of DHP1401 in Patients with Mild to Moderate Alzheimer's Disease Treated with Donepezil: DHP1401 Randomized Trial in Mild to Moderate Alzheimer's Disease (DRAMA). Journal of Alzheimer's Disease, 2022, 87, 391-403.	1.2	1
99	P3-228: A COMPREHENSIVE VISUAL RATING SCALE ON BRAIN MRI: APPLICATION TO ALZHEIMER'S DISEASE, MILD COGNITIVE IMPAIRMENT, AND SUBJECTIVE MEMORY IMPAIRMENT. , 2014, 10, P714-P714.		O
100	P1-132: PATHOGENIC PSEN1 MUTATION DETECTED IN A KOREAN EOAD PATIENT. , 2014, 10, P348-P348.		0
101	IC-P-035: CORRELATION BETWEEN CSF BIOMARKERS AND QUANTIFIED PIB BURDEN IN ALZHEIMER'S DISEASE PATIENTS. , 2014, 10, P21-P22.		0
102	P3-015: Novel PSEN1 mutation (E280K) in a malaysian family., 2015, 11, P625-P625.		0
103	P4-217: Novel A $\hat{l}^2$ specific recombinant monoclonal antibodies with high sensitivity. , 2015, 11, P863-P863.		0
104	P2-018: Novel, probably pathogenic PSEN1 mutation (G209A) in a korean Alzheimer's disease patient., 2015, 11, P488-P488.		0
105	P1-056: Genetics of early-onset Alzheimer's disease (AD) in korea: An update. , 2015, 11, P359-P360.		0
106	P1-057: Novel, probably pathogenic PSEN1 mutation (L232P) in a korean Alzheimer's disease patient., 2015, 11, P360-P360.		0
107	P3â€102: Genetic Screening for TAU (MAPT) Mutations in Korean Early Onset Alzheimer's Disease Patients. Alzheimer's and Dementia, 2016, 12, P858.	0.4	0
108	P1â€125: A Possible Pathogenic Psen2 Mutation, H169N in a Korean Eoad Patient. Alzheimer's and Dementia, 2016, 12, P451.	0.4	0

#	Article	IF	CITATIONS
109	P4-050: Two Novel GRN Mutations in Korean Patients Diagnosed with Early Onset Alzheimer's Disease. , 2016, 12, P1033-P1033.		0
110	[P3–250]: AMYLOID BETA OLIGOMERIZATION IN PLASMA AS A POTENTIAL BLOODâ€BASED BIOMARKER FOR ALZHEIMER's DISEASE. Alzheimer's and Dementia, 2017, 13, P1038.	0.4	0
111	[P4–068]: THREE NOVEL PATHOGENIC VARIANTS IN CLUSTERIN (CLU) ASSOCIATED WITH EARLYâ€ONSET ALZHEIMER DISEASE. Alzheimer's and Dementia, 2017, 13, P1283.	0.4	O
112	[P3–086]: NOVEL AND KNOWN RARE SORL1 MUTATIONS IN KOREAN AD PATIENTS. Alzheimer's and Dementia, 2017, 13, P965.	0.4	0
113	[P3–113]: MUTATIONAL ANALYSIS OF PRNP IN EARLY ONSET ALZHEIMER's DISEASE IN KOREA. Alzheimer's and Dementia, 2017, 13, P977.	0.4	0
114	[P1–162]: GENETIC ANALYSES OF YOUNG PATIENTS WITH ALZHEIMER'S DISEASE FROM NEXT GENERATION SEQUENCING. Alzheimer's and Dementia, 2017, 13, P305.	0.4	0
115	[P2–127]: HIGH FREQUENCY OF ABCA7 MUTATIONS IN PATIENTS WITH EARLYâ€ONSET ALZHEIMER's DISEASE. Alzheimer's and Dementia, 2017, 13, P655.	0.4	0
116	P1â€257: A BLOOD TEST OF AMYLOIDOPATHY FOR DIAGNOSIS OF ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2018, 14, P379.	0.4	0
117	P1â€033: A MULTICENTER, RANDOMIZED, OPENâ€LABEL, PROSPECTIVE TRIAL TO EVALUATE THE SAFETY OF DONEPEZIL HYDROCHLORIDE 23 MG WITH OR WITHOUT INTERMEDIATE DOSE TITRATION IN PATIENTS WITH ALZHEIMER'S DISEASE TAKING DONEPEZIL HYDROCHLORIDE 10 MG: ODESA STUDY. Alzheimer's and Dementia, 2018, 14, P279.	0.4	O
118	P4â€561: DEPRESSIVE MOOD AND COGNITIVE INSTABILITY IN PATIENTS WITH DEMENTIA WITH LEWY BODIES. Alzheimer's and Dementia, 2019, 15, P1534.	0.4	0
119	Differences in quantitative electroencephalogram and voxelâ€based volumetry between encoding and retrieval in amnestic mild cognitive impairment. Alzheimer's and Dementia, 2020, 16, e044426.	0.4	O
120	Effects of Body Weight on the Safety of High-Dose Donepezil in Alzheimer's Disease: Post hoc Analysis of a Multicenter, Randomized, Open-Label, Parallel Design, Three-Arm Clinical Trial. Dementia and Geriatric Cognitive Disorders, 2021, 50, 289-295.	0.7	0
121	Efficacy of the Phosphorylated tau 181 in Differential Diagnosis of the Alzheimer's Disease: A Systematic Review and Meta-Analysis. Dementia and Neurocognitive Disorders, 2014, 13, 129.	0.4	O
122	Neuroprotective effects of tumor necrosis factor- $\hat{l}_{\pm}$ inhibitor on rat hippocampal organotypic slice cultures treated with the $1-42 < i > \hat{l}^2 <  i> \hat{a} \in \hat{l}_{\pm}$ amyloid. , 0, , .		0
123	CSF total tau∫i±â€synuclein ratio improved the diagnostic performance for Alzheimer's disease as an indicator of tau phosphorylation. Alzheimer's and Dementia, 2021, 17, .	0.4	O
124	Digital Trail Making Testâ€Black & White: Normal vs MCI. Alzheimer's and Dementia, 2021, 17, .	0.4	0
125	Comparison of RCF scoring system to clinical decision for the Rey complex figure using machineâ€learning algorithm. Alzheimer's and Dementia, 2021, 17, .	0.4	O
126	Survival in Korean Patients with Frontotemporal Dementia Syndrome: Association with Behavioral Features and Parkinsonism. Journal of Clinical Medicine, 2022, 11, 2260.	1.0	0

#	Article	IF	CITATIONS
127	Neuropsychological test using machine learning for cognitive impairment screening. Applied Neuropsychology Adult, 0, , 1-6.	0.7	0